Randomized Controlled Trial
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jan 7, 2021; 27(1): 107-128
Published online Jan 7, 2021. doi: 10.3748/wjg.v27.i1.107
Table 9 Composition of gut microbiota (based on the most abundant in phylum population) in the probiotic-treated and placebo groups before and after ingestion period
No.
Phylum
Group
Baseline period
Ingestion period
P valuea
1FirmicutesProbiotic-treated69.90 ± 15.9564.13 ± 15.220.037a
Placebo70.66 ± 14.4165.30 ± 14.520.153
2BacteroidetesProbiotic-treated20.63 ± 11.4928.27 ± 14.260.008a
Placebo21.30 ± 12.7226.71 ± 13.930.045a
3ActinobacteriaProbiotic-treated6.11 ± 5.375.07 ± 5.480.237
Placebo5.55 ± 4.904.63 ± 3.610.453
4ProteobacteriaProbiotic-treated2.87 ± 6.392.04 ± 6.050.491
Placebo1.84 ± 4.321.69 ± 3.770.572
5FusobacteriaProbiotic-treated0.23 ± 0.570.34 ± 0.860.701
Placebo0.20 ± 0.941.58 ± 6.570.044a
6VerrucomicrobiaProbiotic-treated0.13 ± 0.570.04 ± 1.660.028a
Placebo0.35 ± 0.190.02 ± 0.070.024a
7CyanobacteriaProbiotic-treated0.09 ± 0.290.07 ± 0.210.537
Placebo0.06 ± 0.240.04 ± 0.100.427
8LentisphaeraeProbiotic-treated0.02 ± 0.050.01 ± 0.080.681
Placebo0.03 ± 0.020.03 ± 0.110.334
9ElusimicrobiaProbiotic-treated0.00 ± 0.010.00 ± 0.030.655
Placebo0.01 ± 0.020.00 ± 0.000.317
10SynergistetesProbiotic-treated0.00 ± 0.000.00 ± 0.000.655
Placebo0.00 ± 0.000.00 ± 0.010.273

  • Citation: Rahayu ES, Mariyatun M, Putri Manurung NE, Hasan PN, Therdtatha P, Mishima R, Komalasari H, Mahfuzah NA, Pamungkaningtyas FH, Yoga WK, Nurfiana DA, Liwan SY, Juffrie M, Nugroho AE, Utami T. Effect of probiotic Lactobacillus plantarum Dad-13 powder consumption on the gut microbiota and intestinal health of overweight adults. World J Gastroenterol 2021; 27(1): 107-128
  • URL: https://www.wjgnet.com/1007-9327/full/v27/i1/107.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v27.i1.107